Japan· JP-3999058F2022
ホスタマチニブナトリウム水和物
A fostamatinib product containing ホスタマチニブナトリウム水和物, registered in Japan by キッセイ薬品工業, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Fostamatinib is registered in 13 of 19 countries.
Countries holding a registration under ATC B02BX09 (fostamatinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Fostamatinib · ATC B02BX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ホスタマチニブナトリウム水和物
- Manufacturer
- キッセイ薬品工業
- Country
- Japan (JP)
- ATC code
- B02BX09
- ATC class
- Fostamatinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
545 interactions on record for fostamatinib.
Graded by severity as the source publishes them — 50 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fostamatinib · interactions on record
545 records
- 50 severe
- 493 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B02BX09
Fostamatinib, as other registers publish it.
- CanadaTAVALISSEMEDISON PHARMA CANADA INC.
- United StatesTAVALISSERigel Pharmaceuticals, Inc.
- CanadaTAVALISSEMEDISON PHARMA CANADA INC.
- United StatesTAVALISSERigel Pharmaceuticals, Inc.
- DenmarkTavlesseInstituto Grifols S.A.
- FinlandTavlesseInstituto Grifols S.A.
- NorwayTavlesseGrifols
- DenmarkTavlesseInstituto Grifols S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fbd95fe0-2d6d-40f4-b797-e80cff01c2a3 GET /v1/drugs/fbd95fe0-2d6d-40f4-b797-e80cff01c2a3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１５０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999058F2022",
"category": "内用薬",
"price_yen": 6226.8,
"generic_name": "ホスタマチニブナトリウム水和物",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about fostamatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.